Alvogen Expands Operations In Asia

US-based Alvogen has established operations in Asia and has opened an office in Shanghai, China that will lead efforts to commercialize the company’s products in the country. Alvogen China will serve as a global sourcing unit for active pharmaceutical ingredients (API) and finished products that will be used throughout the company’s regional business units that includes North America, Europe and Asia.

Robert Wessman, executive chairman of Alvogen, said: “We see great opportunities for our business in Asia, and the creation of Alvogen China is integral to our development strategy. Through registration of our own products, portfolio acquisitions and strategic partnerships, we aim to build a strong presence in the market with a targeted product offering. We are committed to identifying new alliances in China that will further strengthen our development, manufacturing and sourcing capabilities.”

Qin Maximilian Lue, who is the primary shareholder of Shanghai-based Mephax Holdings, will become the managing director of Alvogen China, and will lead a newly recruited team. Dr Lue has over 20 years of experience in the global medical and pharmaceutical market.

Doug Drysdale, chief executive officer of Alvogen, said: “Within the next five years we aim to be one of the strongest pharmaceuticals companies in China, recognized for our reputation of high quality products and services. It is our vision to build a leaner and more flexible multinational operation that overcomes the challenges of the traditional generics business model.”